Core Insights - The article discusses a collaboration agreement between the Hong Kong-listed innovative drug company,药捷安康 (02617.HK), and the NASDAQ-listed company Neurocrine to develop NLRP3 inhibitors for treating various diseases [1] Company Overview -药捷安康 was established in April 2014 and is headquartered in Nanjing. The company currently has no products on the market, with projected revenue of 0 for the first half of 2025 [1] - The company went public on the Hong Kong Stock Exchange on June 23 this year [1] - As of November 3, the total market capitalization of药捷安康 is approximately HKD 75 billion, down from a peak of nearly HKD 270 billion in September [1] Collaboration Agreement - The agreement grants Neurocrine exclusive rights to develop, manufacture, and commercialize the NLRP3 inhibitors from药捷安康's drug platform outside of Greater China [1] -药捷安康 is entitled to receive an upfront payment and potential milestone payments related to development and commercialization progress, with a total potential value of USD 881.5 million [1] Product Pipeline - The company's research and development focus includes oncology, inflammation, and cardiovascular metabolic diseases, with a pipeline consisting of six clinical-stage candidates and several preclinical candidates [1] - TT-02332 is identified as a preclinical-stage NLRP3 inhibitor developed for treating metabolic and inflammatory diseases [2]
药捷安康一款药物出海